Trial Profile
Entecavir and Lamivudine in patients with HBeAg-negative chronic hepatitis B patients with or without cirrhosis; incidence of Hepatocellular carcinoma.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Oct 2015
Price :
$35
*
At a glance
- Drugs Entecavir (Primary) ; Lamivudine
- Indications Liver cancer
- Focus Therapeutic Use
- 28 Oct 2015 Results published in the Journal of Viral Hepatitis 22:120-7, No.2, 2015-02-01
- 28 Oct 2015 New trial record